Accessibility Menu

Yarrow Bioscience(NASDAQ) YARW

Market Cap$111.16MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-99%
5 Year-97%
1 Year+304%
1 Month+120%
$41.21
+9.31%
+3.51Today
Yarrow Bioscience last closing stock price
MetricPriceDate
Last closeUSD 41.642026-08-06
Yarrow Bioscience stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+26.2%USD 32.992026-07-30
1 month+120.35%USD 18.892026-07-07
3 month+123.42%USD 18.642026-05-08
Year to date+154.42%USD 16.362025-12-31
1 year+304.36%USD 10.302025-08-06
3 year-68.66%USD 132.872023-08-07
5 year-96.86%USD 1,325.302021-08-06
Since inception-99.45%USD 7,636.972020-03-10

Yarrow Bioscience Financials at a Glance

Market Cap

$111.16MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$454.00K

Net Income (TTM)

-$21.46M

EPS (TTM)

-$26.68

P/E Ratio

-1.56

Dividend

$0.00

Beta (Volatility)

1.04 (Average)

Price

$41.21

Volume

18,524.689

Open

$37.02

Previous Close

$41.64

Daily Range

$37.02 - $42.50

52-Week Range

$7.91 - $42.50

Estimated Earnings Date

Aug 13, 2026

YARW News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Yarrow Bioscience

Yarrow Bioscience Inc is a clinical-stage biotechnology company dedicated to developing innovative therapies for autoimmune thyroid diseases. The company's lead product candidate, YB-101, aims to be a first-in-class anti-thyroid stimulating hormone receptor monoclonal antibody, targeting conditions such as Graves' disease and thyroid eye disease.

Products and Services
  • YB-101: A monoclonal antibody targeting TSHR for autoimmune thyroid diseases
  • Research and development focused on transformative therapies
  • Potential future products addressing unmet medical needs in thyroid disorders
Growth Outlook
  • Significant market potential in autoimmune thyroid disease treatments
  • Strong pipeline with ongoing clinical trials for YB-101
  • Increasing awareness and diagnosis of thyroid disorders driving demand
Financial Highlights
  • Recent quarterly revenue of $86,000, showing early commercial activity
  • Cash and short-term investments totaling $24.9 million as of March 31, 2026
  • Current ratio of 20.86 indicates strong liquidity position
Yarrow Bioscience Inc is positioned in a growing sector with a focus on addressing significant health challenges. The company's innovative approach to autoimmune thyroid diseases, particularly through YB-101, presents a unique opportunity for potential investors. The financial metrics indicate a solid liquidity position, which is crucial for supporting ongoing research and development efforts. With a strong cash reserve and a promising product pipeline, Yarrow Bioscience Inc is well-equipped to navigate the complexities of the biotechnology landscape.
AI Generated • Jul 30, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

10

CEO

Rebecca Velez Frey, PharmD

Website

www.yarrowbioscience.com

Headquarters

New Haven, CT 06513, US

YARW Financials

Key Financial Metrics (TTM)

Gross Margin

98.68%

Operating Margin

-5367.62%

Net Income Margin

-4726.21%

Return on Equity

-69.57%

Return on Capital

-107.15%

Return on Assets

-82.93%

Earnings Yield

-64.10%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$111.16MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.67M

Volume

18.52K

Avg. Volume

18.55K

Financials (TTM)

Gross Profit

$448.00K

Operating Income

-$24.37M

EBITDA

-$21.69M

Operating Cash Flow

-$25.74M

Capital Expenditure

$0.00

Free Cash Flow

-$25.74M

Cash & ST Invst.

$24.93M

Total Debt

$0.00

Yarrow Bioscience Performance Analysis

Yarrow Bioscience annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 477,000-48.8%
20232023-12-31USD 424,000-11.1%
20242024-12-31USD 501,00018.2%
20252025-12-31USD 570,00013.8%
Yarrow Bioscience sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-65.8%
Q32025-09-30144.9%
Q42025-12-31-23.1%
Q12026-03-31-33.8%
Yarrow Bioscience annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -11.34-99.1%
20232023-12-31USD -138.481121.2%
20242024-12-31USD -46.77-66.2%
20252025-12-31USD -30.96-33.8%
Yarrow Bioscience sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3035.0%
Q32025-09-30-30.8%
Q42025-12-3141.2%
Q12026-03-3116.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$86.00K

-57.4%

Gross Profit

$80.00K

-60.4%

Gross Margin

93.02%

N/A

Market Cap

$111.16MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$11.12M

N/A

Employees

10

N/A

Net Income

-$3.59M

+58.4%

EBITDA

-$3.58M

+58.4%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$24.93M

-50.4%

Total Debt

$0.00

-100.0%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

-100.0%

Return on Assets

-82.93%

N/A

Return on Invested Capital

-98.91%

N/A

Free Cash Flow

-$4.08M

+64.4%

Operating Cash Flow

-$4.08M

+64.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
KALAKALA BIO, Inc.
$0.74+5.11%
QNRXQuoin Pharmaceuticals, Ltd.
$4.57+4.58%
BCLIBrainstorm Cell Therapeutics Inc.
$0.80+3.90%
SNGXSoligenix, Inc.
$0.38-1.07%

Trending Stocks

Symbol / CompanyPricePrice Chg
TTDThe Trade Desk
$17.67-0.07%
SPCXSpace Exploration Technologies
$114.92+0.06%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$26.93-0.03%
TQQQProShares Trust - ProShares UltraPro Qqq
$72.03-0.01%

Questions About YARW

What is the current price of Yarrow Bioscience?

Yarrow Bioscience is trading at $41.64 per share.

What is the 52-week range for Yarrow Bioscience?

Over the past 52 weeks, Yarrow Bioscience has traded between $7.91 and $42.50.

How much debt does Yarrow Bioscience have?

As of the most recent reporting period, Yarrow Bioscience reported total debt of $0.00.

How much cash does Yarrow Bioscience have on hand?

Yarrow Bioscience reported $24.63M in cash and cash equivalents in its most recent financial results.

What is Yarrow Bioscience’s dividend yield?

Yarrow Bioscience does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services